- Method for obtaining pure enantiomers of a pyridazinone derivative
-
The present invention relates to a method for preparing optically active enantiomers of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile (I), particularly (-) enantiomer of (I). Furthermore, the invention relates to a novel crystalline polymorphic form of the (-) enantiomer.
- -
-
-
- (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]pr
-
Optically substantially pure (-) enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono)propanedinitrile or pharmaceutically acceptable salt thereof, intermediates and a process for the preparation are described. The product is useful as a cardiotonic agent, antihypertensive and vasodilator for the treatment of congestive heart failure.
- -
-
-
- Novel pyridazinone compounds, compositions thereof and method of use
-
New heterocyclic compounds of formula I STR1 in which Het means one of following groups; STR2 wherein R11, R13 and R14 mean independently hydrogen, hydroxymethyl or lower alkyl group, Z means S, O or NH; A means valency bond, --CH=CH--, or --CH2 --CH2 --group; R1 and R2 independently means nitro, cyano, halogen, amino, carboxamido, aryl, aroyl, pyridyl, alkoxycarbonyl, acyl or one of following groups; STR3 wherein R6 means hydrogen or lower alkyl group, R8 means lower alkyl, R7 means cyano or COOR10, wherein R10 means hydrogen or lower alkyl or R1 and R2 together form a substituted or unsubstituted 5 or 6 membered ring which may contain 1 or 2 heteroatom N; R3, R4, and R5 mean independently hydrogen, hydroxy or lower alkyl group; Y means N or CH. The compounds may be used in the treatment of congestive heart failure.
- -
-
-
